A recent global survey showed: 70% of specialist physicians that, for those who have received treatment for women with early breast cancer, the greatest fear is that cancer recurrence and metastasis, such a fear even more than they are for the first time that they suffered from breast cancer. Breast cancer is currently the treatment of cancer, one of the best, as long as the risk of successful control of recurrent breast cancer patients can have a very long lifetime.
1-3 years following breast cancer surgery the most critical: For breast cancer patients, the five years following breast cancer surgery at high risk of relapse period to 1 to 3 years after the highest risk. The event of a recurrence or metastasis of breast cancer, treatment will greatly increase the difficulty may be a direct threat to the patient’s life. Data showed that breast cancer metastasis, the patient’s survival rate will be significantly reduced, such as bone metastases 5-year survival rate was about 16% of the 5-year survival rate of lung metastasis was 12%, while the 5-year survival of liver metastasis rate is almost zero.
In general, breast cancer recurrence in various forms, mainly of local recurrence, contralateral new hair and distant metastasis. The new hair is the opposite side of the mastectomy, the other side of the breast breast cancer occurred. Usually, after one side of breast cancer, contralateral breast primary risk of breast cancer will increase by 3-4 times. Refers to distant metastasis of breast cancer through blood Road to move to distant parts of the body, such as the lung, bone, liver and other organs or tissue. Nearly two-thirds of breast cancer often lead to recurrence of breast cancer, distant metastasis, and distant metastasis of breast cancer death led to the greatest incentive. Therefore, experts say, to prevent recurrence and metastasis of breast cancer five years, need to adopt a scientific approach to determine treatment options and should also encourage and support patient care and use. ATAC landmark study of 100 months, the latest data show that anastrozole reduces overall risk of breast cancer recurrence and metastasis and significantly prolong disease-free survival; even in the four years after the completion of standard therapy, its protective effect is still sustainable.
Thus, early medicine, scientific medicine and of breast cancer patients with long-term benefits. Experts suggest that patients who meet the conditions (ie, hormone-sensitive early breast cancer patients), as soon as possible after the operation the use of appropriate drug treatment means and standard adjuvant therapy for breast cancer, endocrine program. So as to win the longer the patient’s survival time and a better quality of life. If we can take positive and effective means to reduce the recurrence risk of cancer of the road you can go 5 years, 9 years or even longer.
